Learn about new #BTKinhibitor options, antibodies, BCL2 inhibitors, & cellular therapy for #CLL treatment from @DrMDavids @AdamKittai @wwierda & Dr. Lamanna! This activity from #ASCO23 provides clear guidance & strategies for optimal treatment: https://t.co/YuFAL21ldw @PeerView (@CllSociety)

📢 In this trial, pirtobrutinib showed efficacy in patients with heavily pretreated CLL or SLL who had received a covalent BTK inhibitor @NEJM Read➡️https://t.co/me8JOkT0VG #MedTwitter @Daver_Leukemia @LeukemiaRF @LLSResearch @LYM_MM_CONNECT @lymphomahub @Lymphoma_Doc (@bloodmeded)

Register for @OncLive's State of the Science Summit: Leukemia/Lymphoma Updates in Myelofibrosis w/ program chair @JeannePalmerMD. Topics include: ➡BTK Inhibitors in MCL ➡Bispecific Antibodies in DLBCL ➡CAR T-Cell Therapy ➡Updates in CLL ➡Live Q&A https://t.co/CdVQnUkgVP (@MayoCancerCare)

According to Jeff Sharman, MD, "#acalabrutinib, as monotherapy or in combination with #obinutuzumab, resulted in a statistically significant and clinically important improvement" of treatment outcomes for #CLL. Learn more: https://t.co/HblQBmtzgO @jeff_sharman (@OncLearnNetwork)

FDA Accepts sBLA for Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma https://t.co/u7ixzHC9qm via @onclive (@VivekSubbiah)

Seymour et al @BloodJournal Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in ELEVATE-RR https://t.co/nfEj9EAsjI #CLLsm (@chanyooncheah)

Another point was that in studying a Btki ( Zanubrutinib) they found it can enter lymphnodes. I wonder why they found CLL cells in lymphnodes in the HOVON 158 trial IV past therapy by doing a fine needle biopsy. Q and A is always interesting. (@BStuetz)

Vitroretineal lymphoma usually MYD88+. I would consider radiotherapy + BTKi if not able to go to transplant. I believe there is also some data on Len Maintenance... Whatever is cheaper in Argentina! (@GuiperiniMD)

Congratulations to @DeepJagMD for representing #CleClinicCancer in the newly-published results of Pirtobrutinib in NEJM. Great to have more access to this important new treatment for our patients with #CLL, #CLLSociety https://t.co/zShB1AP8ou (@BrianHill_MDPhD)

#17ICML | @tobyeyre82 (@OUHospitals) discusses the results of a MAIC of venetoclax vs. pirtobrutinib for patients with R/R CLL previously treated with a covalent BTK inhibitor: 🎥 https://t.co/w2TCvto7Im @icmlugano #CLLsm #LeuSM #HemOnc (@VJHemOnc)

The utility of an endpoint (and its surrogacy or otherwise) is not only disease-specific, but also, as @DrJFriedberg highlights, therapy-specific That lesson was also important for ibrutinib’s initial approval in CLL (lymphocytosis) (@Eddie_Cliff)

#Hematology Preclinical characterization of #pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor | ⁦@BloodJournal⁩ | American Society of Hematology ⁦@ASH_hematology⁩ #lymsm #leusm #CLL #CLLsm https://t.co/ygyIwu0O5E (@DrRaulCordoba)

The CD20-targeted CAR T-cell therapy MB-106 led to responses and was well tolerated in patients with Waldenström macroglobulinemia who were refractory to a BTK inhibitor. @mshadman @fredhutch @EHA_Hematology #EHA2023 #oncology https://t.co/NEbQErcVsD (@OncLive)

Pirtobrutinib in Covalent BTK Inhibitor Pretreated MCL @JCO_ASCO: These data directly inform regulatory approval, and provide rationale for planned and ongoing studies comparing covalent to non-covalent BTKi in several hematological malignancies. https://t.co/TDPTaQczQA (@DrJFriedberg)

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia @NEJM https://t.co/ZKhMzBOkRq (@VivekSubbiah)

In a single-center phase 1/2 trial, MB-106 produced ongoing responses and a favorable safety profile in patients with Waldenström macroglobulinemia who were refractory to a BTK inhibitor. @mshadman @fredhutch @EHA_Hematology #EHA2023 #oncology https://t.co/ViIyzyXWFW (@OncLive)

At #EHA2023, @ScarfoLydia & @Othman_Al_Sawaf had a fascinating discussion on BTK inhibitors in CLL, sequencing these agents, unmet needs in CLL, and more! Listen to the podcast now: 🎧 https://t.co/CxqtdXexpw #CLLsm #LeuSM #HemOnc (@VJHemOnc)

Thanks for sharing, the question now CAR-T vs Pirtobrutinib in BTK/BCL2 refractory CLL ? Same question with MCL in BTK refectory patient (@5lna_)

Young male patient with mantle cell lymphoma del17p+, tp53 mut not detected, refractory to R-DHAP, now on R-ibrutinib. Would you go for allo in Cr1? No pirto or cart available in 🇦🇷 in case of relapse. @tobyeyre82 @michaelwangmd (@laura_korin)

Med. professionals: earn #CME credit and hear @JohnPLeonardMD on a Q&A panel discussing BTKi-combination therapy in chronic lymphocytic #leukemia (CLL) and small lymphocytic #lymphoma (SLL) via this HMP Edu./ @OncLearnNetwork webcast. https://t.co/qSPAXpUbeZ (@WCMLymphoma)

The superior benefit of zanubrutinib vs BR for patients with CLL or SLL was confirmed with extended follow-up data from the SEQUOIA trial. @mshadman @fredhutch @icmlconf #leusm #oncology https://t.co/snNzveYdy5 (@OncLive)

WATCH: @kmaddmd, and @DanilovLab, of @cityofhope, discuss the use of Bruton tyrosine kinase inhibitors for the treatment of relapsed/refractory mantle cell lymphoma. #lymsm #hematology https://t.co/0Q98E0H0Iz (@OncLive)

Post-ASCO Lung Cancer: In this video, Drs. @JackWestMD, @christine_lovly, and @Alfdoc2 look at data on Sunvozertinib's use against EGFR Exon 20 NSCLC. https://t.co/xvqYxoFOok For more, please visit https://t.co/7Xpzj7KaFx. (@cancerGRACE)

Extended follow-up from the phase 3 SEQUOIA trial demonstrated that zanubrutinib maintained a PFS benefit vs BR in previously untreated patients with CLL or SLL. @mshadman @fredhutch @icmlconf #leusm #oncology https://t.co/IRE3uHgRdx (@OncLive)

@Othman_Al_Sawaf berichtet, in welchen Punkten #Pirtobrutinib bei #rrCLL gegenüber #Venetoclax nicht unterlegen ist: https://t.co/TWJBmF82d1 #Hämatologie #EHA23 @UniCologne @TheCrick @uclcancer @SwantonLab (@MT_Onkologie)

Join Dr. Davids @DrMDavids for our Complimentary Live Interactive CME/CNE Webinar on BTK Inhibitors in B-Cell Cancers! Register Now for tomorrow’s session at 1:00 PM EST: https://t.co/ZsNGQU7ALn #hematology #FOAmed #leukemia #education #CME #CNE #Medlearninggroup (@MLG_CME)

I’ve had patients with CLL and pruritus on different therapies (BTKi and ven-based) - some with hematologic complete response from a CLL-standpoint. Referred to cutaneous oncology and all got started on gabapentin with significant improvement/resolution. (@bitafakhri)

There is no RCT trial reported yet which tells us if one approach (BTKi continuous vs time limited BTKi + Ven vs time limited VenG) is better for frontline CLL, including del17p. However, cross trial comparison shows best long term PFS with continuous BTKi. 1/2 (@NitinJainMD)

ELEVATE-RR showed acala safer and same PFS vs ibrutinib in relapsed CLL ALPINE showed zanu safer and improved PFS compared to ibrutinib in relapsed CLL. No data for acala vs zanu. Given safety, and extrapolating from R/R CLL, acala/zanu preferred for frontline as well (@NitinJainMD)

I generally use second generation BTKi continuous for del17p and/or TP53 mutated CLL (outside of clinical trial setting) (@NitinJainMD)

65/♂️/ newly diagnosed CLL, needs treatment. IGHv unmutated and del17p. ECOG 1. No co-morbidities !! What's your treatment of choice?? •Ven-G •Ven-Ibrutinib •Acalabrutinib •Something else #MedTwitter @NicoGagelmann @Eddie_Cliff @matthew_mei (@nihardesai7)

@nihardesai7 @NicoGagelmann was going to come here to say this - in TP53 aberrant CLL, time-limited therapy is less appealing / effective, so continuous 2nd Gen BTKi seems the best approach (As per Prof John Seymour below!) @thomaseliotlew @victorshiyulin #lymsm (@Eddie_Cliff)

Post-ASCO Lung Cancer: In this video, Drs. @JackWestMD, @christine_lovly, and Alfredo Addeo look at data on Sunvozertinib's use against EGFR Exon 20 NSCLC. https://t.co/xvqYxoFOok For more, please visit https://t.co/3VETMT8eM4. (@cancerGRACE)

Zanubrutinib Maintains PFS Benefit With Extended Follow-up in Previously Untreated CLL/SLL @mshadman @fredhutch @icmlconf #leusm #oncology https://t.co/UPxH0f8lnX (@OncLive)

#EHA2023 ❘ Watch an exclusive discussion between leading #CLL experts @Othman_Al_Sawaf and Lydia Scarfò about updates & questions on the use of covalent and non-covalent BTK inhibitors in CLL. 🎥: https://t.co/xM6ePH4tD4 @EHA_Hematology #CLLsm #HemOnc (@VJHemOnc)

Ibrutinib Rituximab vs Rituximab, no better CR but better marginally PFS in frontline follicular #lymsm #17icml https://t.co/iACgf78kyf (@HayderSaeed_MD)

#EHA2023 Lydia Scarfò and @Othman_Al_Sawaf discuss the latest advances in BTK inhibitors for #CLL (@CLLAdvocates)

Join Lydia Scarfò and @Othman_Al_Sawaf as they discuss the latest advances in BTK inhibitors for patients with CLL in our latest session filmed at #EHA2023 🎥. Click here: 👉https://t.co/QVhMqj9SlY👈 @EHA_Hematology #CLLsm #HemOnc (@VJHemOnc)

Rituximab and Ibrutinib in frontline MZL #lymsm showing a ORR 91% and 2 yr PFS 77% #17icml https://t.co/DmB1fnQdn7 (@HayderSaeed_MD)

Well happy to see 94% prior BTKi here, TRANSCEND-CLL had only 36-45% prior BTK I believe… which seems like a strange population not reflective of real world CLL population. (@DrPaulyDeSantis)

TRANSCEND NHL 001 Liso-cel for mantle cell lymphoma @michaelwangmd #17ICML - 88 pts - median 3 prior lines - 94% prior BTKi - 23% TP53mut - 8% CNS disease (@Eddie_Cliff)

SELENE RCT of ibrutinib vs placebo + RCHOP or BR in R/R FL or MZL #17ICML: - 403 pts randomized, vast majority FL, most got BR - no difference in PFS or OS (same for small MZL subgroup) - more high grade AEs in ibr arm Not surprising, but 7 yrs of f/u is great. #lymsm (@majorajay)